Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;7(4):458-66.
doi: 10.1002/jcsm.12107. Epub 2016 Mar 7.

Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients

Iris J G Rutten  1 , David P J van Dijk  2 , Roy F P M Kruitwagen  1 , Regina G H Beets-Tan  3 , Steven W M Olde Damink  2 , Toon van Gorp  1
Affiliations

Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients

Iris J G Rutten et al. J Cachexia Sarcopenia Muscle. 2016 Sep.

Abstract

Background: Malnutrition, weight loss, and muscle wasting (sarcopenia) are common among women with advanced ovarian cancer and have been associated with adverse clinical outcomes and survival. Our objective is to investigate overall survival (OS) related to changes in skeletal muscle (SM) for patients with advanced ovarian cancer treated with neoadjuvant chemotherapy and interval debulking.

Methods: Ovarian cancer patients (n = 123) treated with neoadjuvant chemotherapy and interval debulking in the area of Maastricht (the Netherlands) between 2000 and 2014 were included retrospectively. Surface areas of SM and adipose tissue were defined on computed tomography at the level of the third lumbar vertebra. Low SM at baseline and SM changes during chemotherapy were compared with Kaplan Meier curves, and Cox-regression models were applied to test predictors of OS.

Results: Median OS for patients who lost SM (n = 83) was 916 ± 99 days, which was significantly different from median OS for patients who maintained or gained SM (n = 40), which was 1431 ± 470 days (P = 0.004). Loss of SM was also a significant predictor of OS in multivariable Cox-regression analysis (hazard ratio 1.773 (95%CI: 1.018-3.088), P = 0.043). Low baseline SM did not influence survival.

Conclusions: Patients with ovarian cancer have a worse survival when they lose SM during neoadjuvant chemotherapy. Evaluation of low SM at a specific time point is not prognostic for OS. External and prospective validation of these findings is imperative. Nutritional, pharmacological, and/or physical intervention studies are necessary to establish whether SM impairment can be prevented to prolong ovarian cancer survival.

Keywords: Body composition; Computed tomography; Induction chemotherapy; Ovarian neoplasms; Sarcopenia; Survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Body composition analysis with SliceOmatic®.
Figure 2
Figure 2
Flow diagram.
Figure 3
Figure 3
Survival proportions: baseline skeletal muscle index.
Figure 4
Figure 4
Survival proportions: changes in skeletal muscle.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, 2013.
    1. Surveillance, Epidemiology, and End Results (SEER) Program SEER 9 Incidence & U.S. Mortality Research Data (1973–2011). In: National Cancer Institute D, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission, editor.
    1. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE‐‐5‐a population‐based study. Lancet Oncol 2014;15:23–34. - PubMed
    1. du Bois A, Reuss A, Pujade‐Lauraine E, Harter P, Ray‐Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO‐OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234–1244. - PubMed
    1. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943–953. - PubMed

LinkOut - more resources